3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended September 30, 2022:
+Added: The following table summarizes the activity, by month, during the three months ended March 31, 2023:
Period Total Number of
6 unchanged sentences
Purchased Under
−Removed: July 9,066 $ 2.35 $ 3,995,621
−Removed: August 12,713 2.33 3,966,063
−Removed: September 11,331 2.47 3,938,105
−Removed: 10.1* Ninth Amendment to Revolving Credit Loan Agreement, dated as of September 29, 2022, by and between Cumberland Pharmaceuticals Inc.
−Removed: and Pinnacle Bank.
+Added: January 18,122 $ 2.60 $ 3,706,634
+Added: February 10,663 2.63 3,678,628
+Added: March 58,044 1.94 3,565,836
+Added: 10.1* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J.
+Added: Kazimi and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.11 of the Company’s Current Report on Form 8-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
+Added: 10.2* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.12 of the Company’s Current Report on Form 8-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
+Added: 10.3* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.13 of the Company’s Current Report on Form 8-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
+Added: 10.4* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.14 of the Company’s Current Report on Form 8-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
+Added: 10.5* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M.
+Added: Hamm and Cumberland Pharmaceuticals Inc.
+Added: (incorporated by reference to Exhibit 10.15 of the Company’s Current Report on Form 8-K, File No.
+Added: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: November 14, 2022 By:
+Added: May 12, 2023 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.